CARDIO DIAGNOSTICS HOLDINGS (CDIO)

US14159C1036 - Common Stock

0.3666  -0.03 (-8.12%)

After market: 0.368 +0 (+0.38%)

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (9/27/2023, 7:16:53 PM)

After market: 0.368 +0 (+0.38%)

0.3666

-0.03 (-8.12%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)N/A N/A
Ins Owners24.66%
Inst Owners4.61%
Market Cap2.98M
Shares8.13M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.5
IPO11-23 2021-11-23
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CDIO Daily chart

Company Profile

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2021-11-23. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD, is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its second product, PrecisionCHD, is an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Its Epi+Gen CHD and PrecisionCHD tests are categorized as laboratory-developed tests (LDTs), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers and payors.

Company Info

CARDIO DIAGNOSTICS HOLDINGS

311 W. Superior Street, Suite 444

Chicago ILLINOIS

P: 18552269991.0

Employees: 7